PDCD1 and cancer: Blockade of PD-1/PD-L1 binding by the administration of either an anti-PD-1 or anti-PD-L1 antibody overcomes immune resistance in preclinical models [11–17] and has led to remarkable clinical responses in a variety of cancer patients [2, 18–24].